The Manufacturers Life Insurance Company Has $1.11 Million Holdings in NeoGenomics, Inc. (NASDAQ:NEO)

The Manufacturers Life Insurance Company decreased its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 3.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 67,517 shares of the medical research company’s stock after selling 2,170 shares during the quarter. The Manufacturers Life Insurance Company owned 0.05% of NeoGenomics worth $1,113,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. SBI Securities Co. Ltd. bought a new position in NeoGenomics during the fourth quarter worth about $26,000. Sterling Capital Management LLC raised its position in shares of NeoGenomics by 788.7% during the fourth quarter. Sterling Capital Management LLC now owns 3,706 shares of the medical research company’s stock worth $61,000 after purchasing an additional 3,289 shares during the period. Smartleaf Asset Management LLC lifted its holdings in shares of NeoGenomics by 203.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,156 shares of the medical research company’s stock valued at $70,000 after purchasing an additional 2,787 shares in the last quarter. Blue Trust Inc. grew its position in shares of NeoGenomics by 33.2% in the 4th quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company’s stock valued at $73,000 after purchasing an additional 1,103 shares during the period. Finally, KBC Group NV increased its stake in NeoGenomics by 44.7% during the 4th quarter. KBC Group NV now owns 6,557 shares of the medical research company’s stock worth $108,000 after purchasing an additional 2,027 shares in the last quarter. Institutional investors own 98.50% of the company’s stock.

NeoGenomics Stock Performance

NEO opened at $8.36 on Wednesday. The business’s 50-day simple moving average is $9.14 and its 200 day simple moving average is $13.01. NeoGenomics, Inc. has a 52-week low of $6.08 and a 52-week high of $19.12. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.91 and a current ratio of 1.98. The firm has a market capitalization of $1.08 billion, a PE ratio of -13.48 and a beta of 1.60.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Tuesday, April 29th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.06). NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The company had revenue of $168.04 million for the quarter, compared to the consensus estimate of $171.38 million. During the same quarter in the prior year, the company earned ($0.02) EPS. The company’s revenue for the quarter was up 7.6% on a year-over-year basis. As a group, sell-side analysts expect that NeoGenomics, Inc. will post -0.2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on NEO shares. The Goldman Sachs Group reduced their price target on shares of NeoGenomics from $15.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, April 30th. Needham & Company LLC reduced their target price on shares of NeoGenomics from $18.00 to $8.50 and set a “buy” rating for the company in a research note on Tuesday, April 29th. Leerink Partnrs cut NeoGenomics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 30th. Bank of America cut their price target on NeoGenomics from $19.00 to $16.00 and set a “neutral” rating on the stock in a report on Wednesday, February 19th. Finally, StockNews.com raised NeoGenomics from a “sell” rating to a “hold” rating in a research report on Tuesday. Six investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $13.83.

Insider Activity

In other NeoGenomics news, COO Warren Stone purchased 5,700 shares of the business’s stock in a transaction on Monday, May 12th. The stock was acquired at an average price of $8.58 per share, with a total value of $48,906.00. Following the acquisition, the chief operating officer now directly owns 108,280 shares of the company’s stock, valued at $929,042.40. This trade represents a 5.56% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Jeffrey Scott Sherman acquired 20,000 shares of NeoGenomics stock in a transaction on Friday, May 2nd. The shares were bought at an average cost of $7.51 per share, with a total value of $150,200.00. Following the completion of the transaction, the chief financial officer now owns 158,494 shares of the company’s stock, valued at approximately $1,190,289.94. This trade represents a 14.44% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 65,600 shares of company stock valued at $512,438. 2.40% of the stock is owned by company insiders.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.